In our recent paper (5), we noted that DC engineered to express the Type-1 transactivator protein T-bet (DC.Tbet) and injected directly into sarcomas growing progressively in C57BL/6 mice, led to the cross-priming of protective immunity that was independent of host CD11c+ or BATF3+ DC or the ability of the injected DC.Tbet to migrate to SLO. The gene discussed is ITGAX; the disease is sarcoma.